Phase II Study of RAD001 in Previously Treated Patients With Metastatic Pancreatic Cancer
- Participants taking part in this research study will be given a study medication-dosing
calendar for each treatment cycle. Each cycle lasts four weeks during which you will
be taking the study drug, RAD001, orally every day.
- Participants will come into the clinic every other week during the time of enrollment.
At each clinic visit blood work will be taken to monitor the participants health and a
physical exam will be performed. CT scans will be repeated every 2 months to assess
- Participants will remain on the study as long as they continue to benefit from the
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To assess progression-free survival of RAD001 at two months in patients with metastatic pancreatic cancer whose disease has progressed on gemcitabine chemotherapy.
Charles Fuchs, MD
Dana-Farber Cancer Institute
United States: Food and Drug Administration
|Beth Israel Deaconess Medical Center||Boston, Massachusetts 02215|
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|